R&D/Clinical Trials

Avak Kahvejian, PhD, a general partner with biotech incubator Flagship Pioneering, discusses how AI is rearchitecting methods—and mindsets—in drug discovery and development.

The company did not provide a reason for the bimagrum trial’s halting.

With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s formula for navigating the new age of innovation, where running from risk is not an option.

Eli Lilly's Orforglipron shows superior results in glycemic control and weight loss compared to oral semaglutide in recent clinical trials.

Helen Sabzevari, PhD, president and CEO of Precigen, explains how Papzimeos, developed using the company’s AdenoVerse platform, became the first FDA-approved therapy for adult patients with recurrent respiratory papillomatosi.

Marc Stapley, CEO of Veracyte, reviews upcoming developments in the diagnostic space.

Sanofi's stock plummets over 10% as Amlitelimab's Phase III trial results raise concerns about the company's future pipeline and Dupixent's patent expiration.

The OSE Immunotherapeutics CEO discusses recent develops with this potentially game-changing space in oncology.

Marc Stapley, CEO of Veracyte, discusses the importance of ongoing evidence collection.

Marc Stapley, CEO of Veracyte, discusses new approaches to diagnostics and how its transforming cancer care.

Are we letting momentum outpace readiness?

Pharm Exec unveils its new slate of rising leaders in the biopharma industry—profiling the stories of five executives steering innovative scientific and strategic pursuits in R&D, market access, and patient support.

A mission leader in next-generation pursuits around targeted therapy.

Pioneer of cell-reset technology steers science-to-startup transformation.

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains committed to future treatments.

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with promising RNA interference programs.

Results from the Phase III NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) trials demonstrated that ianalumab significantly reduces disease activity and shows a favorable safety profile in adults with active Sjögren’s disease.

Gene Mack, CEO of Gain Therapeutics, outlines the company’s strategic approach to advancing GT-02287 through potential collaborations and financing options as they await critical Parkinson’s disease trial data.

Results from the Phase III CONVOKE trial (NCT05838625) showed that CT-155 demonstrated a favorable safety profile consistent with previous studies in patients with schizophrenia.

Eli Lilly’s investigational, once-daily oral GLP-1 receptor agonist orforglipron produced a 12% body weight reduction in a Phase III trial, slightly lower than Novo Nordisk’s Wegovy.

Gene Mack, CEO, GAIN Therapeutics, highlights early Phase Ib data showing GT-02287 may enhance neuroprotection across a wider spectrum of Parkinson’s patients regardless of genetic status.

Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit over placebo in post-bunionectomy surgical pain relief.

Despite missing the primary endpoint, SB-01 demonstrated durable clinical improvements and consistent results in the Phase III MODEL trial (NCT05516992), reinforcing its potential as a non-surgical treatment for chronic low back pain associated with degenerative disc disease.

Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined outpatient regimen aimed at accelerating enrollment and regulatory review in the Phase II ALPHA3 trial (NCT06500273).

Gene Mack, CEO, GAIN Therapeutics, outlines how early trial results for GT-02287 are shaping the company’s strategy for advancing a potential new treatment for Parkinson’s disease.